Oncolytics to present reovirus research results

Oncolytics Biotech will present multiple research reports on oncolytic reovirus studies at the American Society of Clinical Oncology meeting. "Reolysin," the company's proprietary formulation of the human reovirus, has been demonstrated to replicate specifically in tumor cells bearing an activated Ras pathway. Reolysin may represent a novel treatment for Ras activated tumour cells and some cellular proliferative disorders. Oncolytics release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.